Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of TX200-TR101 after kidney transplant
NL-OMON56013Not yet recruiting
- Sponsor
- Sangamo Therapeutics
- Start
- Jun 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of TX200 in kidney allograft rejection and organ allograft rejection (2 arms), sponsored by Sangamo Therapeutics. Primary endpoints: Overall survival and Serious adverse events. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
TX200
03
Conditions
kidney allograft rejectionorgan allograft rejection
Beyond the preview
Go deeper on NL-OMON56013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56013.